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Abstract
Background: BRCA2 gene expression is tightly regulated during the cell cycle in human breast cells. The
expression of BRCA2 gene is silenced at the G0/G1 phase of cell growth and is de-silenced at the S/G2 phase.
While studying the activity of BRCA2 gene promoter in breast cancer cells, we discovered that this promoter has
bi-directional activity and the product of the reverse activity (a ZAR1-like protein, we named ZAR2) silences the
forward promoter at the G0/G1 phase of the cell. Standard techniques like cell synchronization by serum starvation,
flow cytometry, N-terminal or C-terminal FLAG epitope-tagged protein expression, immunofluorescence confocal
microscopy, dual luciferase assay for promoter evaluation, and chromatin immunoprecipitation assay were
employed during this study.
Results: Human BRCA2 gene promoter is active in both the forward and the reverse orientations. This promoter is
8-20 fold more active in the reverse orientation than in the forward orientation when the cells are in the non-
dividing stage (G0/G1). When the cells are in the dividing state (S/G2), the forward activity of the promoter is 5-8
folds higher than the reverse activity. The reverse activity transcribes the ZAR2 mRNA with 966 nt coding sequence
which codes for a 321 amino acid protein. ZAR2 has two C4 type zinc fingers at the carboxyl terminus. In the G0/
G1 growth phase ZAR2 is predominantly located inside the nucleus of the breast cells, binds to the BRCA2
promoter and inhibits the expression of BRCA2. In the dividing cells, ZAR2 is trapped in the cytoplasm.
Conclusions: BRCA2 gene promoter has bi-directional activity, expressing BRCA2 and a novel C4-type zinc finger
containing transcription factor ZAR2. Subcellular location of ZAR2 and its expression from the reverse promoter of
the BRCA2 gene are stringently regulated in a cell cycle dependent manner. ZAR2 binds to BRCA2/ZAR2 bi-
directional promoter in vivo and is responsible, at least in part, for the silencing of BRCA2 gene expression in the
G0/G1 phase in human breast cells.
Background
The tumor suppressor protein BRCA2 is implicated in
the regulated growth and proliferation of human breast
[1-4], prostate [5,6], ovarian [7,8], esophageal [9], and
pancreatic [10,11] cells. About 25% of autosomal domi-
nant familial breast cancers are proposed to be caused
by germline mutations in BRCA2 gene [12,13]. The
mutations of BRCA2 gene predispose the cells towards
neoplastic development. BRCA2 protein is over-
expressed in most of the sporadic breast cancer cells
[1-4]. The consequence of this over-expression of
BRCA2 is not clearly understood. The notion could be
that unique cellular mechanisms are triggered in the
breast cancer cells to stimulate BRCA2 gene expression
as a temporary measure to regulate the growth of the
breast cancer cells. One potential mechanism of BRCA2
involvement in breast cancer progression may be
through deregulation of the BRCA2 gene expression.
In humans, BRCA2 is a 3418-amino acid protein loca-
lized in the nucleus [14,15]. Loss of BRCA2 function has
been shown to lead to centrosome amplification, chro-
mosomal rearrangement, aneuploidy, and reduced
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ble-strand break repair. BRCA2 is known to directly
bind to RAD51, BCCIP, PALB2, and BRAF35 proteins
that are involved in meiotic/mitotic recombination,
DNA double-strand break (DSB) repair, and chromo-
some segregation [1-4,15].
BRCA2 gene expression is stringently regulated during
the cell cycle. BRCA2 expression is proportional to the
rate of cell proliferation [14,16]. While BRCA2 expres-
sion is involved in cell cycle checkpoints and DNA
repair, the mechanisms of cell cycle-dependent regula-
tion of BRCA2 gene expression remains elusive. Analysis
of the minimal promoter sequence of BRCA2 recognized
several conserved binding sites for transcription factors
such as E-box, E2F, and Ets recognition motifs
[15,17-20]. USF1 and USF2 bind to the E-box [18,19]
and Elf1, an Ets family protein, binds to the Ets recogni-
tion motifs [18] to activate BRCA2 gene expression
[18,19]. Another transcription factor, NF-B, has also
been shown to bind to the promoter and induce BRCA2
gene expression [19]. The tumor suppressor protein
TP53 represses the BRCA2 promoter by blocking the
binding of USF [20]. Recently, poly-(ADP-ribose) poly-
merase-1 was reported to negatively regulate BRCA2
gene promoter by binding to it [15].
We have reported previously that the transcriptional
repressor protein SLUG negatively regulates BRCA2
gene expression in SLUG-positive breast cancer cells by
binding to an E2-box flanked by two Alu sequences in
the -701 to -921-bp region [17,21]. Deletion of this
sequence resulted in a 5-7-fold activation of the BRCA2
promoter. But the mechanism of cell cycle dependent
regulation of BRCA2 gene expression in SLUG-negative
cells remains unclear.
Here, we provide experimental evidence for the bi-
directional activity of human BRCA2 gene promoter.
We have shown here that the reverse activity of this
promoter indeed transcribes a protein (ZAR1-like, we
named ZAR2) that has significant similarity (36% iden-
tity), particularly at the C-terminal amino acid sequence
of the C4-type zinc finger containing homeodomain
protein, zygote arrest 1 (ZAR1) [22,23]. The similarity
between ZAR1 and ZAR2 may indicate that these pro-
teins belong to a unique family of transcriptional regula-
tors. The chromosomal context of BRCA2 and ZAR2
genes are highly conserved among vertebrates studied.
BRCA2 and ZAR2 gene expressions are reciprocally
related during the cell cycle in human breast cells. Our
studies suggest that negative regulation of BRCA2 gene
expression by the ZAR2 at the G0/G1 phase of human
breast cell growth may provide an additional mechanism
of cell cycle-dependent regulation of its expression in
both SLUG-positive and SLUG-negative cells.
Methods
Cell culture and synchronization
Human breast cancer cells were obtained from ATCC
(Manassas, VA) and cultured in ATCC-recommended
media [21,24]. We synchronized the cells by serum star-
vation and evaluated by FACS analysis, as described ear-
lier [21]. For transfection and synchronization
experiments, we transfected the cells with the plasmids
(see below) and let them recover for 2 h in RPMI med-
ium with 10% fetal bovine serum (FBS). This complete
medium was then replaced with starvation medium
(RPMI 1640, phenol red free, 0% FBS). After 36 h, the
cells were stimulated to re-enter the proliferative cell
cycle by replacing the starvation medium with medium
containing 20% FBS. Cells were harvested at specific
time points following serum stimulation and were pro-
cessed. The progression of cells through the cell cycle
during these experiments was monitored by flow cyto-
metric analysis of replicate samples of propidium
iodide-stained cells [18,21]. Each transfection experi-
ment was repeated at least twice with triplicate samples
each time. We used different human cell types including
human mammary epithelial cells (HMEC), human breast
cancer cells like MCF7, MDA-MB-468, MDA-MB-231,
BT549, as described [21], for further verification and
confirmation experiments.
Promoter constructs, transfection and dual luciferase
assay
The human BRCA2 gene promoter (-187 to +310) was
PCR amplified from the genomic DNA using primers P1
and P2 (Table 1), and cloned into pCR2.0-Topo (Invi-
trogen, Carlsbad, CA). The cloned insert (497 bp) was
digested with Eco RI and cloned at the Eco RI site of
the pRL-Null vector (Promega, Madison, WI). The
resulting plasmids, pRL-FP (forward promoter) and
pRL-RP (reverse promoter) (Fig. 1B), were transiently
transfected into MCF7 cells using Lipofectamine 2000
transfection reagent (Invitrogen) along with the pGL3-
control vector (Promega). Protein lysates were prepared
from the cells, and dual-luciferase activities were mea-
sured as described previously [21,24]. Renilla luciferase
(Rluc) activity was normalized with respect to firefly
luciferase (Fluc) activity and presented as a ratio (rela-
tive light units; RLU). We also made a dual reporter
construct (Fig. 1B) in which the BRCA2/ZAR2 promoter
sequence is flanked by two reporter gene ORFs, Rluc is
transcribed by forward (BRCA2) activity and Fluc is
transcribed by the reverse (ZAR2) activity. To clone the
firefly luciferase (Fluc) gene opposite to the Rluc gene in
pRL-FP, Fluc ORF was taken out from pGL3-basic plas-
mid with Hind III and Sal I digestions and the DNA
fragment was gel purified. The Fluc ORF was then
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dual reporter plasmid pRL-DR. The identities of the
plasmid constructs were verified by restriction mapping
and nucleotide sequencing.
GeneRacer analysis of ZAR2 gene transcription start site
The transcription start site of the ZAR2 gene was deter-
mined with the reagents from the GeneRacer Kit (Invi-
trogen). RNA was isolated from MCF7 cells using
TRIzol reagent. The DNAse (RQ1, Promega)-treated
RNA was then digested with calf intestinal phosphatase
to remove 5’-phosphate from broken RNAs (if any). The
5’-caps of the intact mRNAs were removed by digestion
with tobacco acid pyrophosphatase followed by ligation
of a RNA oligonucleotide (44 nt) by T4 RNA ligase fol-
lowing suppliers protocols and using their reagents.
These RNAs were used as template to make the
cDNAs with GeneRacer oligo(dT) primer. The 5’-end of
the ZAR2 mRNA was amplified using the GeneRacer
5’-primer and ZAR2 gene specific antisense primer
(P3 and P4, Table 1) and Platinum Pfx DNA polymerase
(Invitrogen). The PCR conditions were 1 cycle at 94°C
for 2 min; 5 cycles at 94°C for 30 sec, 72°C for 2 min; 5
cycles at 94°C for 30 s, 70°C for 2 min; 25 cycles at 94°
C for 30 sec, 60°C for 30 s, and 68°C for 2 min, and
1 cycle at 68°C for 10 min. The PCR product (814 bp:
770 bp from the ZAR2 mRNA + 44 bp from the RNA
anchor) was gel purified, cloned and the nucleotide
sequences were determined [21,24].
Expression of 3X-FLAG tagged ZAR2 in MCF7 cells
Human ZAR2 (hZAR2) gene ORF (NM_001136571; 1-
966 bp) was PCR amplified from the cDNAs derived
from MCF7 cells with Hind III and Bam HI site-
containing primers (P5 and P6, Table 1). The reverse
primer did not have the endogenous stop codon. The
PCR product was cloned at the Hind III/Bam HI sites of
p3xFLAG-CMV-14 vector (Sigma Chemical Co. St
Louis, MO) to get the C-terminal FLAG tagged con-
struct. For the expression of N-terminal FLAG-tagged
ZAR2, ZAR2 ORF was amplified from the cDNAs
derived from MCF7 cells with Hind III and Xba I site-
containing primers (P7 and P8, Table 1). The reverse
primer retained the endogenous stop codon. The PCR
product was cloned at the Hind III/Xba I sites of
p3xFLAG-CMV-10 vector (Sigma). The clones were
sequence verified. The plasmid DNA was transfected in
the MCF7 cells using Lipofectamine 2000 (Invitrogen)
following supplier’s protocol. After 36 h, cells were lyzed
in TRIzol (Invitrogen) for RNA isolation or in Cell lytic
Table 1 Sequences of the oligonucleotides used in this study.
Oligo Name Sequence (5’-3’) Purpose Product size
P1 TCAGCGAGAAGAGAACAC BRCA2/ZAR2 gene promoter amplification 497 bp
P2 TTGGCAGAGACAAAAGGGC
P3 CGACTGGAGCACGAGGACACTGA Gene racer ZAR2 5’-RACE 814 bp
P4 GCTGTTTGTGCCCTGAGAGTCC
P5 AAGCTTATGGAGCGCTTTGTCCGT PCR of C-terminal FLAG-tagged ZAR2 975 bp
P6 GGATCCCATCACATATTTAAAGCTGTAAA
P7 AAGCTTATGGAGCGCTTTGTCCGT PCR of N-terminal FLAG-tagged ZAR2 978 bp
P8 TCTAGATCACATCACATATTTAAAGCTGTAAAT
P9 CACTGTAAAGATTGTAAGACCAGG ZAR2 RT-PCR 140 bp
P10 CTGACATTGGATTGCTTCTACTCG
P11 GTACAGGAAACAAGCTTCTGA BRCA2 RT-PCR 271 bp
P12 GACTAACAGGTGGAGGTAAAG
P13 GCTCGTCGTCGACAACGGCTC Beta-actin RT-PCR 352 bp
P14 CAAACATGATCTGGGTCATCTTCTC
P15 ACCCUUACAAGAGGGCGCAGCUUAA siRNA#1
P16 UUAAGCUGCGCCCUCUUGUAAGGGU
P17 UCCUGUGGCAAUAUUUACAGCUUUA siRNA#2
P18 UAAA GCUGUAAAUAUUGCCACAGGA
P19 ACCACAUGAGAGCGGCGACUUCUAA Control siRNA#1
P20 UUAGAAGUCGCCGCUCUCAUGUGGU
P21 UCCCGGUAUAAAUUUCGACUGUUUA Control siRNA#2
P22 UAAACAGUCGAAAUUUAUACCGGGA
P23 ATCACTACTTGTCATCGTCATCCTTGTAGTCG FLAG reverse primer
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Page 3 of 19Figure 1 Cell cycle dependent bi-directional activities of human BRCA2 gene promoter. (A) Genomic context of human BRCA2 gene bi-
directional (BD) promoter studied. The numbers shown are with respect to the transcription start site of human BRCA2 gene. (B) Maps of the
reporter constructs in pRL-Null vector used in the study. (i) The single reporter constructs: pRL-FP (forward construct) and pRL-RP (reverse
construct); (ii) the dual reporter construct. URS: upstream regulatory sequence; Ex-1: exon 1; Int-1: intron 1; Rluc: Renilla luciferase; Fluc: firefly
luciferase; ORF: open reading frame. (C) Activities of the BRCA2 (forward) and the ZAR2 (reverse) promoters in different lines of human breast
cancer cells at G0/G1 and S/G2 phases of their cell cycles. Results are mean ± SE (n = 6). The differences between the G0/G1 and S/G2 phase
cells were statistically significant (shown by ‘*’; p < 0.001).
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blotting analysis [21,24]. Stable transfectants were also
selected in G418 (1000 μg/ml) containing growth
medium.
Immunofluorescence analysis
Cells were transfected in 6-well plate with either the C-
terminal FLAG-tagged construct (p3XFLAG-CMV14 or
p3XFLAG-CMV14-ZAR2) or with the N-terminal FLAG
tagged constructs (p3XFLAG-CMV10 or p3XFLAG-
CMV10-ZAR2) using Lipofectamine 2000 (Invitrogen).
After 16 h of transfection, cells were trypsinized and
plated in 8-well chamber slides for 24 h in complete
growth medium, washed with PBS, fixed with ice-cold
methanol for 10 min and permeabilized in 50 mM
NH4Cl and 0.2% Triton X100 in PBS. After blocking
with 5% goat serum in PBS, the cells were incubated
with anti-FLAG M2 monoclonal antibody (Sigma) in the
blocking buffer overnight at 4°C [24]. After 16 h, the
slides were washed 5 times with PBS and treated with
secondary antibody conjugated with the red fluorescent
d y e( A l e x aF l u o rR 5 5 5 - c o n j u gated donkey anti-mouse
IgG, Invitrogen) for 1 h at room temperature. When
performed dual labeling, unsynchronized MCF7 cells
expressing C-terminal FLAG-tagged ZAR2 protein were
processed similarly but incubated with both anti-FLAG
M2 mouse monoclonal antibody (Sigma) and cyclin A
monoclonal rabbit antibody (Abcam, Cambridge, MA)
in the blocking buffer overnight at 4°C. After 16 h, the
slides were washed 5 times with PBS and treated with
secondary antibody conjugated with the red fluorescent
d y e( A l e x aF l u o rR 5 5 5 - c o n j u gated donkey anti-mouse
IgG, Invitrogen for FLAG) and the green fluorescent dye
(Alexa Fluor R488-conjugated donkey anti-rabbit IgG,
Invitrogen for cyclin A) for 1 h at room temperature.
The cells were subsequently washed with PBS four
times and stained with DAPI (Sigma) or Topro (Invitro-
gen). Finally, each slide was examined by confocal fluor-
escence microscopy (Nikon TE2000-U-CI confocal
microscope). Each representative image was examined
and digitally recorded at the same cellular level and
magnification [24].
Real time RT-PCR
Total RNA was isolated from cultured cells using TRIzol
reagent (Invitrogen) according to the manufacturer’s
instructions. Isolated RNA was treated with DNase
(RQ1, Promega) and then first strand cDNA was synthe-
sized for real-Time RT-PCR (19). First strand cDNAs
were synthesized using iScript cDNA synthesis kit
(Biorad) with 5 μg of total RNA per reaction. For the
real-time RT-PCR reaction cDNA (0.5 μl) was used per
well in a total reaction volume of 25 μl. The iQSYBR
green supermix (Biorad) containing the antibody-
mediated hot start iTaq DNA polymerase was used for
the PCR reaction. RT-PCR conditions were 1 cycle at
95°C for 3 min; 40 cycles at 95°C for 30 sec and 55°C
for 1 min; 1 cycle at 95°C for 1 min; 1 cycle of 55°C for
1 min then 80 cycles for 10 sec each with 0.5°C incre-
ment after cycle two starting at 55°C, to collect the melt
curve data and hold at 20°C [21,24]. The end point RT-
PCR was done using Taq PCR master mix (Qiagen).
PCR conditions were 1 cycle at 94°C for 5 min; 40
cycles: 94°C for 1 min, 55°C for 1 min and 72°C for 1
min; 1 cycle at 72°C for 10 min and then hold at 4°C.
Quantitative Chromatin Immunoprecipitation (ChIP)-PCR
Analyses (qChIP-PCR)
MCF7 cells stably transfected to over express C-terminal
F L A G - t a g g e dZ A R 2w e r eu s e df o rt h i ss t u d y .C h I P
assays were done with the EZ MagnaChIP kit reagents
and protocols (Upstate-Millipore). Briefly, cells were
treated with formaldehyde (1% final concentration) for
10 min at 37°C. Cross-linking was terminated with addi-
tion of glycine (0.125 M final concentration). Cells were
washed twice with ice-cold PBS containing protease
inhibitor cocktail (Sigma). The chromatin pellets were
sonicated in SDS lysis buffer [1% SDS, 10 mM EDTA,
50 mM Tris (pH 8.1)] to an average DNA size of 500
bp with a Fisher model 50 Sonic Dismembranator using
an optimized sonication condition. The sonicated
extract was centrifuged for 10 min at maximum speed
and diluted with ChIP dilution buffer (0.01% SDS, 1.1%
Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl (pH
8.1), 167 mM NaCl). The diluted ChIP lysates were pre-
cleared with Magna beads for 30 min at 4°C. Immuno-
precipitations were performed at 4°C overnight with
either FLAG (Sigma) or normal mouse IgG (Santa Cruz
Biotechnology). After 1 h incubation with 20 μlP r o t e i n
A-Magna beads suspension, the conjugates were col-
lected by magnetic separator. Immunocomplexes were
washed twice sequentially in low salt immune complex
wash buffer [0.1% SDS, 1% Triton X-100, 2 mM EDTA,
20 mM Tris-HCl (pH 8.1), 150 mM NaCl], high salt
immune complex wash buffer [0.1% SDS, 1% Triton X-
100, 2 mM EDTA, 20 mM Tris-HCl (pH 8.1), 500 mM
NaCl], LiCl immune complex wash buffer [0.25 M LiCl,
1% IGEPAL-CA-630, 1% deoxycholic acid, 1 mM
EDTA, 10 mM Tris (pH 8.1)], and TE buffer [10 mM
Tris-HCl, 1 mM EDTA (pH 8.0)]. Elution of the immu-
nocaptured chromatin complexes were performed with
ChIP elution buffer provided in the kit. The DNA-
protein cross-linking was reversed by incubating at 62°C
for 2 h with Proteinase K. DNA fragments were
obtained using Qiagen DNA purification column. DNA
samples and standards were analyzed using real-time
PCR system (BioRad) and iQSYBR Green PCR Master
Mix (BioRad). Primers used to amplify BRCA2/ZAR2
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ing cycling parameters were used: 95°C for 3 min, 40
cycles of 95°C for 15 s, 55°C for 30 s, and 72°C for 1
min. Dissociation curve analyses were performed to con-
firm specificity of the amplification products. All sam-
ples were run in triplicate and all data were normalized
with control IgG and 1% input DNA amplification
[21,24].
Knockdown of ZAR2 gene expression
ZAR2 mRNA was knocked down in MCF7 cells using
50 pmol/ml of ZAR2 specific stealth siRNA#1 (P15 and
P16, Table 1) and stealth siRNA#2 (P17 and P18,
Table 1). Corresponding control stealth siRNAs used
were (#1: P19/P20 and #2: P21/P22, Table 1). Stealth
siRNAs were custom designed and synthesized by Invi-
trogen. Transfection of the cells with siRNAs was done
by lipofection following Invitrogen-provided protocol.
After 68 h cells were lysed in TRIzol for RNA isolation.
F i r s ts t r a n dc D N A sw e r es y n t h e s i z e du s i n gi S C R I P T
cDNA synthesis kit (BioRad). Evaluation of the levels
of ZAR2 and BRCA2 mRNAs was done by real-time
RT-PCR using iQSYBR green Supermix (BioRad). To
evaluate the effect of ZAR2 mRNA knockdown on the
activities of the forward (BRCA2) and the reverse
(ZAR2) promoters, MCF7 cells were transfected with 50
pmol/ml of the ZAR2 or control siRNA for 68 h. The
cells were then transfected with the BRCA2 forward or
reverse promoter containing reporter constructs (Fig. 1).
Dual luciferase assay was performed after 24 h as
described previously [21] following the supplier’s proto-
col (Promega).
Results
Human BRCA2 gene promoter has bi-directional activity
We studied the minimal promoter of human BRCA2
gene as established by several groups [15,17-21] (Fig.
1A). We cloned the 497 bp promoter DNA sequence
(-187 to +310) of human BRCA2 gene in front of
Renilla luciferase (Rluc) gene in pRL-Null plasmid (Pro-
mega) to obtain clones with the insert either in the for-
ward or in the reverse orientation with respect to the
luciferase gene (Fig. 1B). We also developed a dual
reporter construct in which the firefly luciferase (Fluc)
gene ORF is transcribed by the reverse activity of the
cloned promoter and the forward activity of the promo-
ter will transcribe Rluc gene ORF (Fig 1B) from a single
plasmid DNA. The single reporter construct with the
forward orientation of the promoter yielded the BRCA2
gene promoter activity whereas the construct with the
reverse orientation of the promoter revealed the activity
of ZAR2 gene. We found that both the forward and the
reverse orientations of the promoter have significant
promoter activities (Table 2). Surprisingly, the activity of
the reverse promoter was significantly higher in compar-
ison to that of the forward promoter in different human
breast cancer cells. These were unsynchronized cells
with 90-95% confluency and the difference between the
two activities varied depending upon the cell line tested
(Table 2). When these cells were transiently transfected
with the reporter constructs and the promoter activities
were assayed at 40-60% confluency, the forward activity
was higher than the reverse activity (data not shown),
suggesting cell cycle dependency in the regulation of
these promoters.
The forward and the reverse promoter activities are
differentially regulated during the cell cycle
Regulation of BRCA2 gene expression during cell cycle
progression is well-documented [14,18,19,21,25]. To
evaluate whether the forward and the reverse promoter
activities of BRCA2 gene promoter is regulated during
the cell cycle, we synchronized different human breast
cancer cell lines that were transiently transfected with
either of the single-reporter plasmid constructs (Fig. 1B)
and pGL3-Control plasmid (asat r a n s f e c t i o nc o n t r o l ;
Promega). Our data suggest that ZAR2 gene promoter
activity is 2-7 folds higher than the BRCA2 gene promo-
ter activity in the G0/G1 phase cells whereas it is signifi-
cantly less than the BRCA2 gene promoter activity in
the S/G2 phase cells (Fig. 1C). Similar results were
obtained with MCF10A and HMEC cells. The ratio of
the Rluc/Fluc from the cells transiently transfected with
the dual-reporter construct (Fig. 1B) increased when the
cells were shifted to S/G2 phase from G0/G1 phase
(Table 3). These data are in agreement with the sugges-
tion that these two promoters are reciprocally regulated
during the cell cycle.
The bi-directional promoter of BRCA2 gene produces
overlapping transcripts
Human ZAR2 gene is designated in the NCBI database
as ZAR1L (#LOC646799). This gene is recently reported
by in silico analysis in human as well as in bovine cells
Table 2 Relative activities of the forward and the reverse
promoters of BRCA2 gene in different unsynchronized
human breast cancer cells at 95% confluency.
Promoter
orientation
Relative luciferase activity* in
MCF-7 MDA-MB-468 MDA-MB-231 BT549
Forward 2.6 ±0.7 0.9 ± 0.2 1.6 ± 0.2 3.0 ± 0.5
Reverse 22.0 ± 2.1 5.4 ± 0.3 8.7 ± 0.8 15.4 ± 0.1
*Renilla luciferase activities are expressed as relative light units (RLU)
normalized with respect to firefly luciferase activities from the same cellular
extracts. Results are mean ± SE (n = 6).
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with the translation start codon. The 5’-UTR sequence
for ZAR2 mRNA has not yet been reported. Since we
hypothesized that ZAR2 gene is transcribed from the
BRCA2 gene promoter, the transcription start site of
ZAR2 gene should also be located within the 497 bp
promoter. To determine the 5’-UTR as well as the tran-
scription start site of the ZAR2 gene, we employed
GeneRacer technology (Invitrogen). We amplified the
5’-RACE product (814 bp: 770 bp from mRNA + 44 bp
from the Gene Racer RNA anchor) (Fig. 2A) and deter-
mined the nucleotide sequence of the cloned insert.
Alignment of the nucleotide sequence of the 5’-RACE
product with genomic DNA sequence revealed that the
transcription start site (TSS) of ZAR2 is located within
the exon 1 of BRCA2 gene while the exon 1-intron 1
junction of ZAR2 is located within the upstream
sequence of the BRCA2 g e n e( F i g .2 B ) .A sac o n t r o lf o r
the GeneRacer technique, we verified the transcription
start site and the first splice donor site of human
BRCA2 gene in parallel. The locations of the transcrip-
tion start sites and the first splice donor site at the
reverse strand of the BRCA2 gene promoter are shown
in Fig. 2B. Relative maps of the BRCA2 and ZAR2 tran-
scription start sites (TSS) in the bi-directional promoter
tested are shown in Fig. 2C. These data suggest that
BRCA2 and ZAR2 transcripts have 111 nt complemen-
tary and antiparallel overlaps with each other at their
5’-ends (see below).
The genetic arrangements of BRCA2 and ZAR2 genes are
highly conserved among the vertebrates studied
The reciprocal relationship between BRCA2 and ZAR2
genes should be of significant biological importance
because the bi-directional arrangements of these genes
are highly conserved in several vertebrate species
( F i g .3 A ) .D a t a b a s ea n a l y s i s( N C B IG e n B a n k )s h o w e d
that although several other surrounding genes have
changed in their relative positional arrangements,
BRCA2/ZAR2 pair remains intact from bird to human
a n dp e r h a p si no t h e r s( F i g .3 A ) .L i k eB R C A 2 ,Z A R 2i s
present in many vertebrates (Fig. 3B). Unlike BRCA2,
which is found in many organisms from protozoa
to human [26-29], we could not find any significant
ortholog or paralog of ZAR2 mRNA or protein in non-
vertebrates or microbes by database search.
A new exon and a new intron are identified for human
ZAR2 gene
GeneRacer technology revealed a new exon and a new
intron at the 5’-flank of the ZAR2 g e n e( F i g .4 A ) .T h e
new exon 1 of ZAR2 is 245 bp, of which 111 bp and
134 bp are complementary and antiparallel to BRCA2
exon 1 and upstream sequences, respectively. With
respect to BRCA2 gene transcription start site (TSS), the
location of ZAR2 exon 1 is -134 to +111 (Fig. 2). Our
study also revealed 431 bp additional sequences added
before the translation start site of ZAR2 gene (Fig. 4B).
Based upon these analyses, ZAR2 now has 5 exons and
4 introns (Fig. 4A) instead of 4 exons and 3 introns, as
entered in the gene database. Our study revealed that
the translation start site (ATG codon) is located within
exon 2, instead of exon 1.
The 5’-UTR of human ZAR2 mRNA is riddled with
upstream AUG codons
T h en u c l e o t i d es e q u e n c eo ft h eZAR2 cDNA is shown
in Fig. 4B. The 676 nt 5’-untranslated region (UTR) of
the ZAR2 mRNA has several upstream AUG codons
(uAUGs) and out of frame upstream open reading
frames (uORFs). Thus, translation of ZAR2 mRNA may
p o t e n t i a l l yb er e g u l a t e db yt h e s eu A U G sa n du O R F s
[30,31].
ZAR2 protein has strong similarity in amino acid
sequence with ZAR1 and is highly conserved among
vertebrates
The 966 nt coding sequence of the ZAR2 mRNA codes
for a 321 amino acid protein (Fig. 5A). We found two
unique C4 type zinc fingers at the carboxyl terminus of
this protein (Fig. 5A). These fingers are Cys-X2-Cys-
X23-Cys-X2-Cys and Cys-X2-Cys-X24-Cys-X2-Cys
where X is any amino acid. Such zinc fingers are found
in nuclear receptors and GATA family of transcription
factors among others [32]. The uniqueness of the ZAR2
zinc fingers is that they are comparatively longer (23-24
amino acids) than those of other proteins. The ZAR2
protein is largely similar with the ZAR1 protein, particu-
larly at the C-terminus and the zinc finger Cys residues
are highly conserved (Fig. 5B). The zinc fingers are also
highly conserved among the ZAR2 orthologs from dif-
ferent animals (Fig. 6). These analyses suggest that
ZAR2 is a potential transcription factor, perhaps binding
to the promoters of its target genes through its C-term-
inal zinc finger domains. Alternatively, ZAR2 could be a
Table 3 Ratio of the forward (BRCA2) and the reverse
(ZAR2) activity in the G0/G1 and S/G2 growth phases of
different breast cancer cells using transient transfection
with the dual reporter/promoter construct (see Fig. 1B).
Growth
Phase
Ratio of Rluc/Fluc activities* in
MCF7 MDA-MB-
468
MDA-MB-
231
BT549
G0/G1 0.125 ± 0.03 0.23 ± 0.06 0.33 ± 0.01 0.28 ± 0.07
S/G2 3.25 ± 0.14 3.12 ± 0.11 2.5 ± 0.12 3.31 ± 0.13
*Results are mean ± SE (n = 6)
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Page 7 of 19Figure 2 The transcription start sites of the reverse transcript from BRCA2 gene bi-directional promoter. (A) GeneRacer amplification
product for ZAR2. See Materials and methods for details. (B) Nucleotide sequence of human ZAR2/BRCA2 bi-directional promoter. The
transcriptional start sites (TSSs), as determined by GeneRacer technique, are shown. The segment in green color is the sequence complementary
to part of the intron 1 sequence of human BRCA2 gene, the segment in red color is from exon 1 and the blue part is from the upstream
sequence of BRCA2 gene. The E-box sequence essential for BRCA2 gene expression [18,19] is underlined. The splice donor site at the ZAR2 gene
exon 1/intron 1 junction is indicated by a downward arrow. The ‘G’ residue at the SNP site at -26 from BRCA2 gene transcription start site is
shown by a red *. (C) Cartoon showing the human BRCA2 (upper panel) and ZAR2 (lower panel) gene promoter studied. The identities of ZAR2
exon1 (Ex-1) and intron 1 (Int-1) were experimentally determined in this study. TSS: transcription start site (designated as +1); URS: upstream
regulatory sequence.
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Page 8 of 19Figure 3 Conservation of the BRCA2/ZAR2 genetic arrangements in vertebrates. (A) Relative chromosomal locations of BRCA2 and ZAR2
genes in different vertebrates. The maps were obtained from NCBI site for Entrez genes http://www.ncbi.nlm.nih.gov/sites/entrez?
db=gene&term=BRCA2+ Not drawn to the scale. (B) Dendrogram with branch lengths for the ZAR2 proteins from different vertebrates. The
putative ZAR2 protein amino acid sequences were mined from the NCBI Entrez database and dendrogram with branch length was analyzed by
CLUSTALW program http://align.genome.jp/.
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Page 9 of 19Figure 4 The exon-intron structure and mRNA sequence of human ZAR2 gene. (A) Cartoon showing the exon-intron structure of human
ZAR2 gene. The first exon of ZAR2 overlaps with the exon 1 of the BRCA2 gene (not drawn to the scale). (B) Nucleotide sequence of human
ZAR2 mature mRNA. The 5’-UTR sequence was experimentally determined (see text for details). The putative protein coding sequence (ORF) is
shown in blue and highlighted in gray. The upstream AUG (uAUG) codons at the 5’-UTR are highlighted: out-of-frame uAUGs are in yellow
shades; in-frame uAUGs are in green shades. The 5’-UTR sequence overlapping with BRCA2 mRNA sequences are shaded yellow. Rest of the 5’-
UTR sequence of ZAR2 mRNA is derived from the newly identified exon 1 and is shown in red.
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Page 10 of 19non-DNA binding transcriptional regulator like FOG-1
[33] and perhaps regulates the function of BRCA2 gene
promoter by restraining some regulatory protein.
ZAR2 protein is predominantly located in the cytosol of
unsynchronized human breast cells
Subcellular location of a protein often reflects upon its
biological function. To understand subcellular location
of ZAR2 in human breast cells, we expressed N-terminal
and C-terminal FLAG-tagged ZAR2 in these cells (Fig.
7A and 7B). Expression of both of these tagged proteins
was necessary because we did not know whether tagging
will compromise the subcellular localization of this pro-
tein. This was particularly important since the putative
nuclear localization signals of ZAR2 are located at the
C-terminal region of this protein (Fig. 5A). RT-PCR
analysis with ZAR2 specific primer (P9, Table 1) and
FLAG-tag specific primer (P23, Table 1) showed
Figure 5 Analysis of ZAR2 protein sequence. (A) Amino acid sequence of human ZAR2 protein showing the C4 type zinc fingers. Cys
residues of the zinc fingers are underscored and putative nuclear localization signals are highlighted. (B) CLUSTALW alignment between human
ZAR1 (NP_783318) and ZAR2 (NP_001130043) amino acid sequences. hZar1: human ZAR1; hZar2: human ZAR2. Identical amino acid residues are
highlighted in grey and the similar amino acid residues are shown in yellow shades. The conserved C4-type zinc fingers #1 and #2 are also
shown.
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Page 11 of 19significant expression of the recombinant ZAR2 tran-
scripts in the cells transiently transfected with either of
the constructs (Fig. 7A). Similar data were obtained with
Western blot analysis for the FLAG-tagged ZAR2 pro-
tein with anti-FLAG monoclonal antibody (Fig. 7B).
Although ZAR2 is a zinc finger protein with attributes
of a nuclear protein and has putative strong nuclear
localization signals (Fig. 5A), our immunofluorescence
microscopy analysis data with FLAG antibody showed
predominant cytosolic localization of the ZAR2 protein
in the transiently transfected human breast cells (Fig.
7C). This is true for both N-terminal as well as C-term-
inal FLAG-tagged ZAR2 proteins (Fig. 7C). Few cells in
the population had significant levels of FLAG-tagged
ZAR2 inside the nucleus (Fig. 7C). In an unsynchro-
nized population of MCF7 cells transfected with FLAG-
tagged ZAR2 construct also showed major presence of
FLAG-ZAR2 (red) in the cytosol while the S-phase mar-
ker cyclin A (green) is predominantly located in the
nucleus of the cell (Fig. 7D).
Expressions of BRCA2 and ZAR2 during cell cycle are
inversely related
RT-PCR analysis showed the expression of BRCA2 and
ZAR2 mRNAs in unsynchronized dividing human breast
cells (Fig. 8A). To evaluate whether the expressions of
Figure 6 CLUSTALW alignment of ZAR2 amino acid sequences from different vertebrates.h Z a r 2 :h u m a n( Homo sapiens)Z A R 2
(NP_001130043); cZar2: canine (Canis familiaris) ZAR2 (XP_534509); gZar2: chicken (Gallus gallus) ZAR2 (XP_001233594); mZar2: mouse (Mus
musculus) ZAR2 (NP_001153165); rZar2: Rat (Rattus norvegicus) ZAR2 (XP_001071298). Identical amino acid residues are highlighted in grey and
the similar amino acid residues are shown in yellow shades. The conserved C4-type zinc fingers #1 and #2 are also shown.
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Page 12 of 19Figure 7 Over expression of ZAR2 protein and its subcellular location in MCF7 and MDA-MB-231 cells. (A) RT-PCR analysis showing the
expression of N-terminal (i) and C-terminal (ii) FLAG-tagged ZAR2 mRNA in MCF7 cells. ZAR2-1 and ZAR2-2 are two independently derived
transfectants. Similar results were obtained with MDA-MB-231 cells. (B) Western blotting analysis with anti-FLAG antibody showing expression of
N-terminal (i) and C-terminal (ii) FLAG-tagged ZAR2 protein in MCF7 cells. Similar results were obtained with MDA-MB-231 cells. (C)
Immunofluorescence analysis showing predominantly cytosolic location of N-terminal FLAG-tagged ZAR2 protein in the dividing MDA-MB-231
cells (left panel); and the C-terminal FLAG-tagged ZAR2 in dividing MCF7 cells (right panel). Anti-FLAG M2 antibody was used for the detection
of FLAG-tagged ZAR2 protein in the cells. The cells were transiently transfected with the expression plasmid constructs and thus not all cells are
expressing the recombinant protein. (D) Immunofluorescence confocal microscopy after dual labeling of the unsynchronized C-terminal FLAG-
tagged ZAR2-expressing MCF7 cells with reagents for FLAG-ZAR2 (red) and the S-phase marker cyclin A (green). Predominant levels of FLAG-
ZAR2 in the cytosol of the cells that have high levels of cyclin A in the nucleus. Nucleus was stained with Topro for confocal microscopy.
Misra et al. Molecular Cancer 2010, 9:50
http://www.molecular-cancer.com/content/9/1/50
Page 13 of 19Figure 8 Relative expressions of BRCA2 and ZAR2 mRNAs at different cell cycle stages of human breast cells.( A )R T - P C Ra n a l y s i s
showing the expressions of BRCA2 and ZAR2 mRNAs in the unsynchronized (mostly dividing) cells. b-Actin mRNA was used as a loading control.
(B) Real-time RT-PCR evaluation of the relative levels of BRCA2 and ZAR2 mRNAs in different human breast cancer cells at G0/G1 and S/G2
phases. The differences between the G0/G1 and S/G2 phase cells were statistically significant (shown by ‘*’; p < 0.001). (C) Immunofluorescence
confocal microscopy showing growth phase-dependent localization of N-terminal FLAG-tagged ZAR2 protein in the synchronized MCF7 cells.
Anti-FLAG M2 antibody was used for the detection of FLAG-tagged ZAR2 protein in the cells. The cells were transiently transfected with the
expression plasmid constructs and thus not all cells are expressing the recombinant protein.
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Page 14 of 19BRCA2 and ZAR2 genes at G0/G1 and S/G2 phases fol-
low the pattern of their promoter activities, we mea-
sured the mRNA levels by real-time RT-PCR. In all the
cells tested BRCA2 and ZAR2 expressions are inversely
related. ZAR2 mRNA levels are higher at the G0/G1
phase with significant lower levels of BRCA2 mRNA
(Fig. 8B). On the other hand, at the S/G2 phase the
levels of BRCA2 mRNA are significantly higher than
those of ZAR2 mRNAs (Fig. 8B).
ZAR2 is predominantly located in the nucleus of G0/G1
phase human breast cells
We synchronized C-terminal FLAG-tagged ZAR2-
expressing MCF7 cells and evaluated the subcellular
location of this protein at G0/G1 and S/G2 phase by
immunofluorescence confocal microscopy using FLAG
antibody. Our data suggest that ZAR2 protein is predo-
minantly concentrated in the nucleus of these cells at
the G0/G1 phase whereas it is mainly present in the
cytosol at the S/G2 phase cells (Fig. 8C). Evaluation of
ZAR2 protein distribution in the subcellular fractions by
Western blotting analysis also revealed similar localiza-
tion pattern (data not shown). These data suggest that
not only the expression of ZAR2 gene is strictly regu-
lated cell cycle-dependently but its subcellular localiza-
tion is also controlled in a growth stage-dependent
manner. ZAR2 and BRCA2 gene expressions are thus
inversely related.
ZAR2 binds to the BRCA2/ZAR2 gene promoter in vivo
In order to understand the role of cell cycle-dependent
regulation of ZAR2 gene expression on BRCA2 levels,
we explored whether the C4-type zinc finger protein
ZAR2 can bind to the BRCA2 promoter DNA. We used
MCF7 cells over expressing C-terminal FLAG-tagged
ZAR2 and employed quantitative ChIP techniques using
commercially available FLAG antibody for this purpose.
We found that ZAR2 binds tightly with BRCA2/ZAR2
bi-directional promoter preferentially at the G0/G1
phase of MCF7 cells (Fig. 9A and 9B). The nature
(direct or indirect) and exact site(s) of binding of the
ZAR2 protein to this promoter are yet to be determined.
The outcome of over expression of ZAR2 and its bind-
ing to the BRCA2 promoter is not yet known. We
f o u n dt h a to v e re x p r e s s i o na n dD N A - b i n d i n go fZ A R 2
is associated with decrease in the level of BRCA2
mRNA (Fig. 10A) as well as inhibition of both BRCA2
and ZAR2 promoter activities (Fig. 10B), particularly at
the S/G2 phase of MCF7 cells. Correlation between
ZAR2 binding to the promoter and the repression of
BRCA2 gene expression needs to be validated by rigor-
ous mutational analyses.
Figure 9 In vivo binding of ZAR2 protein to the BRCA2/ZAR2
gene promoter. (A) PCR amplification of the immunoprecipitated
chromatin DNA fragment pulled down with FLAG antibody from
synchronized MCF7 cells over-expressing C-terminal FLAG-tagged
ZAR2 protein at the G0/G1 and S/G2 phases. Input DNA (5% was
used as control. Chromatin DNA fragments mock precipitated with
mouse IgG did not significantly amplified any detectable DNA.
BRCA2 gene promoter specific primers [21] were used for PCR
amplifications. (B) Quantitative ChIP analysis of ZAR2 recruitment to
BRCA2/ZAR2 bi-directional promoter in MCF7 cells at G0/G1 and S/
G2 phases. qChIP-PCR analyses were performed with chromatin
extracts harvested from cells over expressing C-terminal FLAG-
tagged ZAR2. The mean values from triplicate data points are
plotted and error bars indicate ± SE. The amplification values are
normalized by subtraction with IgG control antibody and then
division with 1% input DNA. Data shown were representative of
three independent experiments (mean + SE) and the difference
between the G0/G1 phase and the S/G2 phase cells was statistically
significant (shown by ‘*’; p < 0.001).
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Page 15 of 19Knockdown of ZAR2 in the G0/G1 phase stimulated the
expression of BRCA2
To verify further the potential role of ZAR2 in the regu-
lation of BRCA2 gene expression we knocked down the
expression of ZAR2 by two different siRNAs designed
from its ORF. When the mRNA levels of ZAR2 were
knocked down to 50-55% at the G0/G1 phase of MCF7
cells, the levels of BRCA2 mRNA went up significantly
(3.5-4 folds) (Fig. 11A). Interestingly, the activities of
both of the ZAR2 and BRCA2 promoters were increased
in the ZAR2 knocked down cells (Fig. 11B). Increased
expressions of ZAR2 mRNA may explain why we could
not down regulate the ZAR2 mRNA levels more than
50% with the siRNAs.
Discussion
BRCA2 levels go up in many aggressively growing breast
cancer cells [17-21]. It appears that the level of BRCA2
protein in the cell must commensurate with the need of
the cells to avoid detrimental consequences in the cellu-
lar physiology. No BRCA2 in the dividing breast cells
will predispose them to non-homologous end joining
mode of DNA double strand break repair thus to poten-
tial oncogenesis [34]. Understanding the mechanisms of
this stringent mechanism of BRCA2 gene expression
regulation is critical to evaluate etiology of human
breast cancer.
Human genome is riddled with bi-directional promo-
ters [23,35,36]. In this study we characterized the bidir-
ectional promoter that expresses BRCA2 and ZAR2
genes. Human BRCA1 gene and about 11% of the total
other human gene promoters have bi-directional activ-
ities [36]. While assessing the activities of human
BRCA2 gene promoter (Fig. 1A) in both orientations,
reverse orientation serving as a negative control, we
made three significant observations: (i) The human
Figure 10 Effects of over-expression (OVEX) of the C-terminal FLAG-tagged ZAR2 in synchronized MCF7 cells on the BRCA2 and ZAR2
mRNA levels (A) and on the activities of BRCA2 and ZAR2 gene promoters (B) at the S/G2 phase. MCF7 cells were stably transfected with
C-terminally FLAG-tagged ZAR2 and evaluated for their ZAR2 over expression. Levels of the mRNAs were determined by real-time RT-PCR [21].
Promoter activities were measured in MCF7 cells transiently transfected with the single-reporter constructs (Fig. 1B) following the dual luciferase
assay protocols (Promega). pGL3-Control was used as normalization control as described in the ‘Methods’ section. Results are mean ± SE (n = 6).
‘*’ indicates the difference between the corresponding control and the experimental sets is statistically significant (p < 0.001).
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Page 16 of 19BRCA2 gene promoter is active in both the forward and
the reverse orientations; (ii) The BRCA2 gene promoter
is more active in the reverse orientation than in the for-
ward orientation when the cells are in the non-dividing
stage (G0/G1), and (iii) when the cells are in the divid-
ing state (S/G2), the forward activity of the promoter is
higher than the reverse activity (see below). The reverse
activity was insignificant when we did not include the
exon 1 and part of the intron 1 sequence of the BRCA2
gene (26). We have repeated this experiment with differ-
ent human cell types including human mammary
epithelial cells (HMEC), human breast cancer cells like
MDA-MB-468, MDA-MB-231, BT549, immortalized
human breast cells like MCF10A, MCF10AT, human
liver cells HepG2 and human monocytes U937. In all
these cells the promoter behaved similarly. Thus, we
believe that this cell cycle dependent differential bi-
directional promoter activity of the BRCA2 gene is an
intrinsic property of BRCA2 and ZAR2 genes. Recently,
a ZAR2 paralog, Xzar2, has been cloned from the Afri-
can clawed frog Xenopus laevis [36]. Xzar2 was shown
to be involved in epidermal fate determination mainly
through signaling pathways distinct from that of BMP-
Smad during early embryogenesis [37].
As mentioned above, BRCA2 gene expression is tightly
regulated in human breast cells [14,15,17-21]. The
BRCA2 mRNA and protein are only significantly
expressed in the S/G2 phase cells and they are undetect-
able in the G0/G1 phase cells [18-21]. Over expression
of BRCA2 protein was shown to be lethal for the survi-
val of human pancreatic cancer cell line Capan-1 [38].
Several mechanisms are known to be operative in
breast cancer cells to regulate BRCA2 gene expression
[15,18-21]. We reported previously that cell cycle stage-
dependent regulation of BRCA2 gene expression in
SLUG-positive breast cells occurs through a distal E2-
Figure 11 Effect of knockdown of ZAR2 in synchronized MCF7 cells on the BRCA2 and ZAR2 mRNA levels (A) and on the activities of
BRCA2 and ZAR2 gene promoters (B) at the G0/G1 phase. ZAR2 was knocked down in MCF7 cells with two different double-stranded
stealth siRNAs (Invitrogen). Levels of the mRNAs were determined by real-time RT-PCR. Promoter activities were measured in MCF7 cells
transiently transfected with the single-reporter constructs (Fig. 1B) following the dual luciferase assay protocols (Promega). pGL3-Control was
used as normalization control as described in the ‘Methods’ section. Results are mean ± SE (n = 6). ‘*’ indicates the difference between the
corresponding control and the experimental sets is statistically significant (p < 0.001).
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Page 17 of 19box/Alu repeat containing silencer element located
upstream of the BRCA2 gene transcription start site
[17,21]. The zinc-finger transcriptional repressor, SLUG,
binds to the uniquely located E2-box sequence in the
silencer element in the non-dividing cells and blocks the
expression of BRCA2 gene by chromatin remodeling
[21]. We recently found that peroxiredoxin 5 competes
with SLUG for the binding to the BRCA2 gene silencer
in the dividing cells and thus de-silences the expression
of BRCA2 gene in the dividing human breast cells
(Misra, S. and Chaudhuri, G., unpublished). Transcrip-
tion factors other than SLUG that have been reported
to regulate human BRCA2 gene expression include
USF1 and 2 [18-20], P53 [20], NFkB [19], ElF1 [18], and
PARP1 [15]. A recent report indicated the presence of a
SNP (G to A) at the -26 position of human BRCA2 gene
[39]. This SNP is in the exon 1 of ZAR2 gene (Fig. 2B).
Whether TP53 also regulates ZAR2 gene expression and
whether this SNP affects its promoter activity is yet to
be determined.
The bi-directional promoter of BRCA2/ZAR2 gene
produces two partially overlapping transcripts. Whether
these RNAs hybridize with each other and form double-
stranded (ds) RNA and whether this ds-RNA has any
role in regulating the activities of the promoter is yet to
be determined. One of the potential roles of the ds-
RNA could be siRNA-mediated transcriptional gene
silencing through DNA methylation [40,41].
The biological function of ZAR2 protein is not known.
It has two putative C4-type zinc fingers and potentially
could be a transcription factor. We found BRCA2 and
ZAR2 gene expressions have inverse relationships during
the cell cycle. It is possible that ZAR2 protein somehow
inhibits BRCA2 gene expression. Although ZAR2 pro-
tein has two putative NLS sequences, in the dividing
stage of the human breast cells ZAR2 is trapped predo-
minantly in the cytoplasm. Thus, ZAR2 in the dividing
breast cells may not have any significant effect on the
BRCA2 gene expression. At the non-dividing (G0/G1)
phase ZAR2 protein predominantly accumulates in the
cell nucleus, binds to the BRCA2/ZAR2 gene promoter
and consequently, both ZAR2 and BRCA2 gene expres-
sions are inhibited. While it is tempting to speculate
that ZAR2 represents a mechanism of cell cycle depen-
dent regulation of BRCA2 gene expression, direct invol-
vement of ZAR2 in BRCA2 gene transcription is yet to
be determined.
As ZAR2 over expression decreased the levels of
BRCA2 in the cells, this gene, if disregulated, and over
expressed in the cells, it may promote the growth of the
tumor. On the other hand, ZAR2 may be needed to
suppress BRCA2 expression in the quiescent cells.
Expression of BRCA2 in these cells could be detrimental
for the cell growth and survival [37]. We made an
interesting observation while knocking down ZAR2
mRNA levels in different breast cancer cells. Out of four
cell lines tested (MCF7, MDA-MB-231, MDA-MB-468
and BT549), only BT549 died at the G0/G1 phase in the
ZAR2 knocked down cells. We found that ZAR2 knock-
down in the quiescent cells leads to the elevation of the
levels of BRCA2 which should be detrimental to the
cells [38]. But the ability to suppress the growth of the
cells by BRCA2, the cell may need to have high MAGE-
D1 level [42]. Our explanation for the essentiality of
ZAR2 in the BT549 cells is that only these cells among
the four cells tested have high levels of MAGE-D1 [42].
ZAR2 protein thus may have multiple balancing roles in
the biology of BRCA2 and perhaps other molecules in
the cells.
Conclusions
BRCA2 gene promoter has bi-directional activity,
e x p r e s s i n gB R C A 2a n dan o v e lC 4 - t y p ez i n cf i n g e r -
containing transcription factor ZAR2. BRCA2 and
ZAR2 levels in the cells are inversely related with
respect to the cell cycle. Subcellular location of ZAR2
and its expression from the reverse promoter of the
BRCA2 gene are stringently regulated in a cell cycle
dependent manner. ZAR2 accumulates in the nucleus
of the cells at the quiescent stage of the cells and
binds to the BRC2 gene promoter in vivo.Z A R 2i s
responsible, at least in part, for the silencing of BRCA2
gene expression in the G0/G1 phase in human breast
cells.
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